388 related articles for article (PubMed ID: 28102485)
1.
Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
[TBL] [Abstract][Full Text] [Related]
2. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
3. Comparison of
Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of
Moller S; Law I; Munck Af Rosenschold P; Costa J; Poulsen HS; Engelholm SA; Engelholm S
Radiother Oncol; 2016 Oct; 121(1):132-137. PubMed ID: 27622554
[TBL] [Abstract][Full Text] [Related]
6. Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET-PET.
Niyazi M; Jansen N; Ganswindt U; Schwarz SB; Geisler J; Schnell O; Büsing K; Eigenbrod S; la Fougère C; Belka C
J Neurooncol; 2012 Dec; 110(3):389-95. PubMed ID: 23054562
[TBL] [Abstract][Full Text] [Related]
7. Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.
Albert NL; Winkelmann I; Suchorska B; Wenter V; Schmid-Tannwald C; Mille E; Todica A; Brendel M; Tonn JC; Bartenstein P; la Fougère C
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1105-14. PubMed ID: 26666239
[TBL] [Abstract][Full Text] [Related]
8. Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.
Kunz M; Albert NL; Unterrainer M; la Fougere C; Egensperger R; Schüller U; Lutz J; Kreth S; Tonn JC; Kreth FW; Thon N
Neuro Oncol; 2019 Feb; 21(2):274-284. PubMed ID: 29893965
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
10. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
[TBL] [Abstract][Full Text] [Related]
11. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.
Suchorska B; Giese A; Biczok A; Unterrainer M; Weller M; Drexler M; Bartenstein P; Schüller U; Tonn JC; Albert NL
Neuro Oncol; 2018 Jan; 20(2):279-288. PubMed ID: 29016996
[TBL] [Abstract][Full Text] [Related]
12. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET.
Vettermann FJ; Felsberg J; Reifenberger G; Hasselblatt M; Forbrig R; Berding G; la Fougère C; Galldiks N; Schittenhelm J; Weis J; Albert NL; Schüller U
Clin Nucl Med; 2018 Dec; 43(12):895-898. PubMed ID: 30358620
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.
Jansen NL; Suchorska B; Wenter V; Schmid-Tannwald C; Todica A; Eigenbrod S; Niyazi M; Tonn JC; Bartenstein P; Kreth FW; la Fougère C
J Nucl Med; 2015 Jan; 56(1):9-15. PubMed ID: 25537990
[TBL] [Abstract][Full Text] [Related]
16. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [
Romagna A; Unterrainer M; Schmid-Tannwald C; Brendel M; Tonn JC; Nachbichler SB; Muacevic A; Bartenstein P; Kreth FW; Albert NL
Radiat Oncol; 2016 Oct; 11(1):139. PubMed ID: 27769279
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
[TBL] [Abstract][Full Text] [Related]
18. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
19. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.
Jansen NL; Suchorska B; Wenter V; Eigenbrod S; Schmid-Tannwald C; Zwergal A; Niyazi M; Drexler M; Bartenstein P; Schnell O; Tonn JC; Thon N; Kreth FW; la Fougère C
J Nucl Med; 2014 Feb; 55(2):198-203. PubMed ID: 24379223
[TBL] [Abstract][Full Text] [Related]
20. Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Fleischmann DF; Unterrainer M; Corradini S; Rottler M; Förster S; la Fougère C; Siepmann T; Schwaiger M; Bartenstein P; Belka C; Albert NL; Niyazi M
PLoS One; 2019; 14(7):e0216111. PubMed ID: 31339892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
